INSTITUTE OF CHILD HEALTH, Greece

Similar documents
The Centre for Disease Prevention and Control, Latvia

Central Manchester University Hospitals NHS Foundation Trust, UK

National Center for Tumor Diseases (NCT) Heidelberg, Germany

Hospital Carlos Haya. Malaga, Spain

Castilla y leon Regional Health Service (Gerencia Regional de Salud de Castilla y León)

Hospital Universitario de Getafe (Getafe Universitary Hospital), Spain

Erasmus MC, Center for lysosomal and metabolic diseases, Netherlands

Ministry for Health, the Elderly and Community Care, Malta

RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA, Spain

European Society of Cardiology, France

Department of Medical Genetics, Medical School, University of Athens, Greece

Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, SWEDEN

Radboud University Nijmegen Medical Centre, department of Neurology, Netherlands

SERVICIO DE NEUROCIRUGÍA PEDIÁTRICA. HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Spain

Riga East University hospital stationary Infectology Center of Latvia (RAKUS LIC), Latvia

Cystic Fibrosis Europe (CFE), Germany

Schoen Kliniken group, Schoen Klinik Hamburg Eilbek, Dept. of neurology and. neurorehabilitation, Germany

VSOP, Lupus Netherlands

European Haemophilia Consortium

ERN board of Member States

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

ERN Assessment Manual for Applicants

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES

EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)

European Reference Networks (ERN) Guide for patient advocates

ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants

WORK PLAN 2017 LAURENCE BALLIEUX NATIONAL FOCAL POINT. 1 EU 3rd HEALTH PROGRAMME

Member webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016

2nd European Reference Networks Conference 8-9 October Lisbon, Portugal. A report by: G Porto & F Courtois

10 Specialist commissioning

116 Help Lines for Rare Diseases

BELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD)

National Plans for Rare Diseases The French plan Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health

Do terms like FP6, CORDIS, Specific Programme, Call for

EUCERD Joint Action WP7 Workshop From Centres of Expertise for Rare Diseases to European Reference Networks

Executive Report to the European Commission on newborn screening in the European Union

Implementation and adaptation of the European Guidelines into the Romanian public hospitals; the medical physicist role in the Romanian context

The Seventh Framework Programme for candidate and potential candidate countries European Regional Economic Forum Nova Gorica, 30 May 2007

Briefing Paper: Cross-border EU healthcare directive. England and Wales

European Reference Networks: strategic value for the Member States. Perspective of France

A European workforce for call centre services. Construction industry recruits abroad

Background paper. Cross-border healthcare in the EU

Document: Report on the work of the High Level Group in 2006

Call for Nominations. CARLOS V European Award

European Quality Assurance Scheme for Breast Cancer Services

Presenting the European Investment Advisory Hub Annual Forum of the EUSDR, 2015 Ulm. European Investment Advisory Hub 1

Current and future standardization issues in the e Health domain: Achieving interoperability. Executive Summary

1st POs MetabERN Meeting Frankfurt

FP7: Marie Curie Actions

Regulatory Cooperation in Europe. Natalie McCoy, CEER Secretary General INOGATE Conference - Brussels, 1 February 2013

Summary of a Survey on the Europe 2020 Flagship Initiative Innovation Union. Executive Summary

Developing a European Registry for Rare Anaemias

A short paper for ENVI & IMCO MEPs Two solutions to improve recognition of specialisms in the Chapter III professions

COUNCIL OF THE EUROPEAN UNION. Brussels, 12 May 2004 (OR. en) 8913/04 PESC 310 CONOP 14 CODUN 4 COARM 9 RELEX 188

2ème Conférence sur les Réseaux Européens de Référence. 8-9 octobre 2015, Lisbonne. Table ronde ministérielle (8 octobre 12 :15 13 :00)

Specialised Services Service Specification: CP57b. Genetic Testing for Inherited Cardiac Conditions

EPF Workshops on Cross-Border Healthcare 1st Stop: Croatia Meeting Report

EIT HEALTH WILD CARD PROJECTS CALL FOR APPLICATIONS 2018

Simona Bovha, CPCM European Investment Bank. European Investment Advisory Hub

M E D I C AL D I AG N O S T I C T E C H N I C I AN Schematic Code ( )

EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations

Towards the EC Seventh Framework Programme and its support to Research Infrastructures

Cooperation mechanisms EASME

European Social Economy Regions

Call for the expression of interest Selection of six model demonstrator regions to receive advisory support from the European Cluster Observatory

Emergency contingency planning at designated Points of Entry

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

A multi-ethnic multi-national approach to ethical approval of clinical trials involving Thalassaemia patients: the DEEP lesson. Prof.

Info Session Webinar Joint Qualifications in Vocational Education and Training Call for proposals EACEA 27/ /10/2017

A shared agenda for growth: European Commission Services

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL

MELODI. Maximizing European research for radiation protection

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

NHS SCOTLAND APPLICATION FOR REIMBURSEMENT / PERMISSION TO TRAVEL FOR TREATMENT IN THE EUROPEAN ECONOMIC AREA

Legal and financial issues Evaluation process

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. Report on the interim evaluation of the «Daphne III Programme »

The EU Funding landscape. What opportunities for the NHS?

ERC Grant Schemes. Horizon 2020 European Union funding for Research & Innovation

ehealth in caring for people with multimorbidity in European countries

Copernicus Incubation Programme

THE HEALTH SECTOR from EIB lending perspective. Felicitas Riedl

Introduction to ibmg. Marco Varkevisser Director of Education

CALL TEXT AND NATIONAL/REGIONAL REGULATIONS

EFLM EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Spreading Excellence and Widening Participation in Horizon 2020

Jean Monnet support to associations

CAPACITIES WORK PROGRAMME PART 3. (European Commission C (2011) 5023 of 19 July 2011) REGIONS OF KNOWLEDGE

ERN IT Platform delivering the virtual link for the Networks

Membership Welcome Pack 2016 Civil society and social enterprise: power to drive positive change

Investing in future. Marie Skłodowska-Curie Actions current situation and future perspectives

Presentation of Interreg Europe

ANNEX I TO VIII ANNEX I. Health Programme Work Programme for 2017

Justification of Individual Medical Exposures for Diagnosis: A HERCA Position Paper

ERN The way forward: The Member States perspective

National Radiation Safety Committee, HSE

The results will be published on the SCoR website. Individual responses will not be identifiable.

Policies contributing to Health Reforms leading to improved management of Rare Diseases/ Anaemias/ Haemoglobin Disorders in Europe

European Investment Advisory Hub

Job Description. Clinical Nurse Specialist in Breast care. An overview of Breast Cancer Services at the UPMC Beacon Hospital.

Transcription:

INSTITUTE OF CHILD HEALTH, Greece 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: 1. Respondent Profile Academic/public health and healthcare specialised institution/organisation (e.g. Institutes and University Departments of Public Health, Quality, Healthcare, Clinical Excellence) Please indicate level: National level organisation Please indicate for what the administration is responsible: 1.1.1. Other (please specify): 1.2 Please indicate the name of your organisation or centre: INSTITUTE OF CHILD HEALTH. The Institute of Child Health was founded in 196 by Spyros Doxiadis for the promotion of research, education including rare disorder and the provision of specialised child health care services 1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe: 1.4 Please indicate the number of EU Member States and EEA countries (rway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented: 1. If need be, can we contact you by e-mail to obtain further information on your submission? 1..1 Please provide an e-mail address where we can contact you: inchildh@ich.gr EL 1 Yes

1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): 1.7 Please provide additional contact details if needed: Dr Antonios Ganas Administrative Director 0030 213 2037303 2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC). 2.1 How would you describe your organisation's knowledge of CoE and HSHC? 2.1.1 Space for further comments: 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) 2.2.1. Space for further comments: 2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans? 2.3.1 Space for further comments: 2.4. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? Very high Highly specialised healthcare provision Very high High tech diagnostic and treatment services (radiology, nuclear medecine, electrophysiology, radiotherapy etc.) Please specify: 2.. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare? Clinical and Laboratory Diagnosis - follow up Frequently 2..1 Please describe your role in such actions/projects: Members in two national committees of Rare Disorder, EU representation in Cross Border health care expert groups

2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare? Yes 2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? 2.7.1 Space for further comments: They are in development 2.13. What is the scope of the network? 2.14. Which kind of network? 2.14.1 Space for further comments: 2.1. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, = very interested) 2.1.1 Space for further comments: 3. Proposed criteria for ERN (scope, general and specific criteria) 3.1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN 3.1.1. Need of highly specialised healthcare 3.1.1.1. Complexity of the diagnosis and treatment 3.1.1.2. High cost of treatment and resources

3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures 3.1.2. Need of particular concentration of expertise and resources 3.1.2.1. Rare expertise/need of concentration of cases 3.1.2.2. Low prevalence/incidence/number of cases 3.1.2.3. Evaluated experiences of Member States 3.1.3. Based on high-quality, accessible and cost-effective healthcare 3.1.3.1. Evidence of the safety and favourable risk-benefit analysis 3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical) 3.1.4. Do you recommend any additional criteria or option that would effectively address the issue? 4 3.1.. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria? 3.1..1 Explain your proposal in free text: Different groups of inherited Metabolic Disorders e.g. Lysosomal Storage Diseases, Peroxisomal Leykodystrophiews, Congenital Disorders of glycosylation etc all fulfil the ERN criteria and require netw Yes 3.2. General criteria of the centres wishing to join a European Reference Network

3.2.1. Organisation and management 3.2.2. Patients empowerment and centered care 4 3.2.3. Patient care, clinical tools and health technology assessment 3.2.4. Quality, patient safety and evaluation framework policies 3.2.. Business continuity, contingency planning and response capacity 3.2.6. Information systems, technology and e-health tools and applications 3.2.7. Overall framework and capacity for research and training 4 4 3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN 3.2.9. Do you recommend any additional option that would effectively address the issue? 3.2.9.1. Space for further comments: 3.3. Specific criteria regarding the areas of expertise 3.3.1. Competence, experience and good outcomes and care 3.3.2. Specific resources and organisation: 3.3.2.1. Human resources 3.3.2.2. Team/centre organisation

3.3.2.3. Structural conditions 4 3.3.2.4. Specific equipment 3.3.2.. Presence and coordination with other required complementary units or services 3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise 3.3.4. External coordination, care management and follow-up of patients 3.3.. Research, training, health technology assessment in the field of expertise 3.3.6. Specific information systems 4 4 3.3.7. Do you recommend any additional criteria or option that would effectively address the issue? 3.3.7.1. Space for further comments: not applicable